

Ferrosan Medical Devices Holding A/S

Sydmarken 5
2860 Søborg
CVR No. 33388845

Annual report 2022

The Annual General Meeting adopted the
annual report on 09.05.2023

Hans Henrik Pauk Pedersen
Chair of the General Meeting

Contents

Entity details	2
Statement by Management	3
Independent auditor's report	4
Management commentary	7
Income statement for 2022	9
Balance sheet at 31.12.2022	10
Statement of changes in equity for 2022	12
Notes	13
Accounting policies	16

Entity details

Entity

Ferrosan Medical Devices Holding A/S

Sydmarken 5

2860 Søborg

Business Registration No.: 33388845

Registered office: Gladsaxe

Financial year: 01.01.2022 - 31.12.2022

Board of Directors

Peter Henrik Kürstein-Jensen, Chair

Kim Gulstad, Deputy Chair

Staffan Percy Ternström

Arne Due-Hansen

Anja Bach Eriksson

Allan Bjørn Rasmussen

Mia Bielecki

Executive Board

Rasmus Hother le Fevre, CEO

Hans Henrik Pauk Pedersen, CFO

Auditors

Deloitte Statsautoriseret Revisionspartnerselskab

Weidekampsgade 6

2300 Copenhagen S

Statement by Management

The Board of Directors and the Executive Board have today considered and approved the annual report of Ferrosan Medical Devices Holding A/S for the financial year 01.01.2022 - 31.12.2022.

The annual report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2022 and of the results of its operations for the financial year 01.01.2022 - 31.12.2022.

We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.

We recommend the annual report for adoption at the Annual General Meeting.

Søborg, 04.05.2023

Executive Board

Rasmus Hother le Fevre
CEO

Hans Henrik Pauk Pedersen
CFO

Board of Directors

Peter Henrik Kürstein-Jensen
Chair

Kim Gulstad
Deputy Chair

Staffan Percy Ternström

Arne Due-Hansen

Anja Bach Eriksson

Allan Bjørn Rasmussen

Mia Bielecki

Independent auditor's report

To the shareholder of Ferrosan Medical Devices Holding A/S

Opinion

We have audited the financial statements of Ferrosan Medical Devices Holding A/S for the financial year 01.01.2022 - 31.12.2022, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2022 and of the results of its operations for the financial year 01.01.2022 - 31.12.2022 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of this auditor's report. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Entity's ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures in the notes, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.

Copenhagen, 04.05.2023

Deloitte

Statsautoriseret Revisionspartnerselskab
CVR No. 33963556

Nikolaj Thomsen

State Authorised Public Accountant
Identification No (MNE) mne33276

Management commentary

Financial highlights

	2022	2021	2020	2019	2018
	DKK'000	DKK'000	DKK'000	DKK'000	DKK'000
Key figures					
Gross profit/loss	(121)	(183)	(162)	(137)	(312)
Operating profit/loss	(121)	(183)	(162)	(137)	(312)
Net financials	(2)	(13)	(60)	(110)	(1,378)
Profit/loss for the year	(96)	249,543	126,313	110,508	83,181
Total assets	580,997	698,491	572,909	573,094	573,347
Equity	572,605	572,701	572,858	573,045	573,237
Ratios					
Return on equity (%)	(0.02)	43.57	22.05	19.28	15.30
Equity ratio (%)	98.56	81.99	99.99	99.99	99.98

Financial highlights are defined and calculated in accordance with the current version of "Recommendations & Ratios" issued by the CFA Society Denmark.

Return on equity (%):

$\frac{\text{Profit/loss for the year} * 100}{\text{Average equity}}$

Average equity

Equity ratio (%):

$\frac{\text{Equity} * 100}{\text{Total assets}}$

Total assets

Primary activities

Ferrosan Medical Devices Holding A/S is af part of the Ferrosan Medical Devices Group. The Entity's primary activities is to own shares and related activities.

Development in activities and finances

The result for 2022 is a loss of 96 t.DKK. The Entity's balance as of 31 December 2022 shows a total of 580,997 t.DKK and an equity of 572,605 t.DKK.

Profit/loss for the year in relation to expected developments

The result for 2022 is in line with Management's expectations.

Outlook

For 2023, the Entity expects a result in line with 2022 depending on potential dividend from subsidiaries.

Events after the balance sheet date

No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.

Income statement for 2022

	Notes	2022 DKK'000	2021 DKK '000
Other external expenses		(121)	(183)
Gross profit/loss		(121)	(183)
Income from investments in group enterprises		0	249,700
Other financial income	2	2,885	2
Other financial expenses	3	(2,887)	(15)
Profit/loss before tax		(123)	249,504
Tax on profit/loss for the year	4	27	39
Profit/loss for the year	5	(96)	249,543

Balance sheet at 31.12.2022

Assets

	Notes	2022 DKK'000	2021 DKK'000
Investments in group enterprises		572,630	572,630
Financial assets	6	572,630	572,630
Fixed assets		572,630	572,630
Receivables from group enterprises		8,265	125,700
Joint taxation contribution receivable		27	43
Receivables		8,292	125,743
Cash		75	118
Current assets		8,367	125,861
Assets		580,997	698,491

Equity and liabilities

	Notes	2022 DKK'000	2021 DKK'000
Contributed capital		3,776	3,776
Retained earnings		568,829	568,925
Equity		572,605	572,701
Payables to group enterprises		8,345	125,718
Other payables		47	72
Current liabilities other than provisions		8,392	125,790
Liabilities other than provisions		8,392	125,790
Equity and liabilities		580,997	698,491
Events after the balance sheet date	1		
Employees	7		
Contingent liabilities	8		
Assets charged and collateral	9		
Related parties with controlling interest	10		
Transactions with related parties	11		
Group relations	12		

Statement of changes in equity for 2022

	Contributed capital DKK'000	Retained earnings DKK'000	Total DKK'000
Equity beginning of year	3,776	568,925	572,701
Profit/loss for the year	0	(96)	(96)
Equity end of year	3,776	568,829	572,605

Notes

1 Events after the balance sheet date

No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.

2 Other financial income

	2022 DKK'000	2021 DKK'000
Financial income from group enterprises	2,885	0
Exchange rate adjustments	0	2
	2,885	2

3 Other financial expenses

	2022 DKK'000	2021 DKK'000
Financial expenses from group enterprises	2,885	0
Other interest expenses	2	10
Exchange rate adjustments	0	5
	2,887	15

4 Tax on profit/loss for the year

	2022 DKK'000	2021 DKK'000
Adjustment concerning previous years	0	4
Refund in joint taxation arrangement	(27)	(43)
	(27)	(39)

5 Proposed distribution of profit and loss

	2022 DKK'000	2021 DKK'000
Extraordinary dividend distributed in the financial year	0	139,000
Retained earnings	(96)	110,543
	(96)	249,543

6 Financial assets

	Investments in group enterprises DKK'000
Cost beginning of year	572,630
Cost end of year	572,630
Carrying amount end of year	572,630

Investments in subsidiaries	Registered in	Corporate form	Equity interest %	Equity DKK'000	Profit/loss DKK'000
Ferrosan Medical Devices A/S	Søborg	A/S	100.00	333,576	204,600
Ferrosan Medical Devices Sp. z.o.o	Szczecin	z.o.o	100.00	33,414	27,123

7 Employees

The Entity has no employees other than the Executive Board. The Executive Board has not received any remuneration.

8 Contingent liabilities

The Entity participates in a Danish joint taxation arrangement where Moon HoldCo ApS serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore liable for income taxes etc for the jointly taxed entities, and for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly taxed entities. The jointly taxed entities' total known net liability under the joint taxation arrangement is disclosed in the administration company's financial statements.

9 Assets charged and collateral

The Entity has provided security for the Group's bank commitments. The total commitment as pr. 31 December 2022 amounts to DKK 1,855,310 thousand.

10 Related parties with controlling interest

Moon HoldCo ApS, 2860 Søborg, Denmark
 Moon MidCo ApS, 2860 Søborg, Denmark
 Moon BidCo ApS, 2860 Søborg, Denmark
 Ferrosan Medical Devices Group A/S, 2860 Søborg, Denmark
 ApS FMD III, 2860 Søborg, Denmark

11 Transactions with related parties

Only related party transactions not conducted on an arm's length basis are disclosed in the annual report. No such transactions have been conducted in the financial year.

12 Group relations

Name and registered office of the Parent preparing consolidated financial statements for the largest group:
Moon HoldCo ApS, 2860 Søborg, Denmark

Name and registered office of the Parent preparing consolidated financial statements for the smallest group:
Ferrosan Medical Devices Group A/S, 2860 Søborg, Denmark

Accounting policies

Reporting class

This annual report has been prepared in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium).

The accounting policies applied to these financial statements are consistent with those applied last year.

Consolidated financial statements

Referring to section 112(1) of the Danish Financial Statements Act, no consolidated financial statements have been prepared. Ferrosan Medical Devices Holding A/S and its affiliated entities are included in the consolidated financial statements of Ferrosan Medical Devices Group A/S.

Recognition and measurement

Assets are recognised in the balance sheet when it is probable as a result of a prior event that future economic benefits will flow to the Entity, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when the Entity has a legal or constructive obligation as a result of a prior event, and it is probable that future economic benefits will flow out of the Entity, and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.

Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and measurement.

Income is recognised in the income statement when earned, whereas costs are recognised by the amounts attributable to this financial year.

Foreign currency translation

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are translated using the exchange rate at the balance sheet date. Exchange differences that arise between the rate at the transaction date and the rate in effect at the payment date, or the rate at the balance sheet date, are recognised in the income statement as financial income or financial expenses. Property, plant and equipment, intangible assets, inventories and other non-monetary assets that have been purchased in foreign currencies are translated using historical rates.

When recognising foreign subsidiaries and associates that are independent entities, the income statements are translated at average exchange rates for the months that do not significantly deviate from the rates at the transaction date. Balance sheet items are translated using the exchange rates at the balance sheet date. Goodwill is considered belonging to the independent foreign entity and is translated using the exchange rate at the balance sheet date. Exchange differences arising out of the translation of foreign subsidiaries' equity at the beginning of the year at the balance sheet date exchange rates and out of the translation of income statements

from average rates to the exchange rates at the balance sheet date are recognised directly in the translation reserve in equity.

Exchange adjustments of outstanding accounts with independent foreign subsidiaries, which are considered part of the total investment in the subsidiary in question, are recognised directly in the translation reserve in equity.

When recognising foreign subsidiaries that are integral entities, monetary assets and liabilities are translated using the exchange rates at the balance sheet date. Non-monetary assets and liabilities are translated at the exchange rate at the time of acquisition or the time of any subsequent revaluation or writedown. The items of the income statement are translated at the average rates of the months; however, items deriving from non-monetary assets and liabilities are translated using the historical rates applicable to the relevant non-monetary items.

Income statement

Other external expenses

Other external expenses include expenses relating to the Entity's ordinary activities, including administrative expenses. This item also includes write downs of receivables recognised in current assets.

Income from investments in group enterprises

Income from investments in group enterprises comprises dividends etc received from the individual group enterprises in the financial year.

Other financial income

Other financial income comprises interest income, including interest income on receivables from group enterprises and transactions in foreign currency and tax relief under the Danish Tax Prepayment Scheme etc.

Other financial expenses

Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises and tax surcharge under the Danish Tax Prepayment Scheme etc.

Tax on profit/loss for the year

Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.

Balance sheet

Investments in group enterprises

Investments in group enterprises are measured at cost. Investments are written down to the lower of recoverable amount and carrying amount.

Receivables

Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.

Joint taxation contributions receivable or payable

Current joint taxation contributions payable or joint taxation contributions receivable are recognised in the balance sheet, calculated as tax computed on the taxable income for the year, which has been adjusted for prepaid tax. For tax losses, joint taxation contributions receivable are only recognised if such losses are expected to be used under the joint taxation arrangement.

Cash

Cash comprises cash in hand and bank deposits.

Dividend

Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.

Other financial liabilities

Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.

Cash flow statement

Referring to section 86(4) of the Danish Financial Statements Act, the Entity has not prepared a cash flow statement as such statement is included in the consolidated cash flow statement of Ferrosan Medical Devices Group A/S, CVR. No. 37808342.